S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
RYTM · Rhythm Pharmaceuticals, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Rhythm Pharmaceuticals Inc (RYTM)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$88.59
-1.67
(-1.86%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$88.59
$88.45
$91.44
52-WEEK RANGE
$88.59
$74.50
$122.20
What's happening
- RYTM is down 1.86% today, trading at $88.59. — Live quote
- Volume today (32,025) is well below its 3-month average of 757,140. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.73 actual vs. $-0.84 estimated (+12.8%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 9
Buy 12
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (24 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
RYTM
-15.73%
vs S&P 500
-28.51%
1-YEAR RETURN
RYTM
-19.74%
vs S&P 500
-34.30%
6-MONTH RETURN
RYTM
+2.37%
3-MONTH RETURN
RYTM
-15.38%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.73
Est. $-0.84
BEAT +12.8%
2026-04-26 (Q1 2026)
$-0.83
Est. $-0.87
BEAT +4.6%
2026-01-26 (Q4 2025)
$-0.73
Est. $-0.84
BEAT +12.9%
2025-10-26 (Q3 2025)
$-0.82
Est. $-0.74
MISS -11.1%
Valuation Measures & Ratios
Enterprise Value4$6.18B
Forward P/E5—
PEG Ratio6-8.74
Price / Sales (TTM1)25.59
Price / Book735.02
EV4 / Revenue25.76
EV4 / EBITDA—
Profit Margin-85.59%
Operating Margin-83.62%
Return on Equity (ROE8)-80.48%
Return on Assets (ROA9)-44.00%
Avg Volume (3M)757,140
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $7.50B | $5.83B | $6.52B | $3.93B | $3.24B |
| P/E | -36.67 | -28.49 | -33.84 | -22.86 | -12.14 |
| Price/Sales | 32.44 | 30.28 | 39.33 | 27.39 | 26.77 |
| Price/Book | 72.81 | 47.45 | 43.81 | -330.20 | 170.97 |
| EV/Revenue | 32.61 | 30.52 | 39.68 | 27.21 | 26.80 |
| ROE | -198.55% | -166.53% | -129.47% | 1444.68% | -1407.99% |
| ROA | -46.76% | -46.27% | -38.01% | -46.15% | -68.99% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short10,767,698
Change from Prior Settlement+4.66%
% of Float—
Days to Cover (Short Ratio)14.14
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 46.9% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-09-14; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -85.6%. Finnhub fundamentals ↗
- Trailing 52-week price return is -19.7%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on RYTM
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $71.3M | $60.1M | $51.3M | $48.5M | $32.7M | $33.3M | $29.1M | $26.0M |
| Operating income | -$48.6M | -$52.4M | -$52.7M | -$45.3M | -$47.0M | -$43.9M | -$40.5M | -$139.9M |
| Net income | -$49.3M | -$55.6M | -$52.9M | -$46.6M | -$49.5M | -$43.6M | -$32.3M | -$141.4M |
| EPS (diluted) | $-0.73 | $-0.83 | $-0.82 | $-0.75 | $-0.81 | $-0.73 | $-0.55 | $-2.35 |
| EPS (basic) | $-0.73 | $-0.83 | $-0.82 | $-0.75 | $-0.81 | $-0.73 | $-0.55 | $-2.35 |
| Operating margin | -$68 | -$87 | -$103 | -$93 | -$144 | -$132 | -$139 | -$539 |
| Net margin | -$69 | -$93 | -$103 | -$96 | -$151 | -$131 | -$111 | -$544 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Mar '25 | Dec '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $437.3M | $442.3M | $480.2M | $506.9M | $372.7M | $386.7M | — | $392.3M |
| Total liabilities | $220.0M | $204.7M | $210.2M | $211.2M | $239.2M | $223.6M | — | $227.7M |
| Stockholders' equity | $103.0M | $122.9M | $139.1M | $148.8M | -$11.9M | $18.9M | — | $21.7M |
| Total current assets | $426.6M | $430.1M | $466.9M | $494.8M | $360.7M | $369.3M | — | $374.2M |
| Total current liabilities | $123.6M | $103.2M | $105.9M | $104.3M | $129.5M | $111.8M | — | $115.5M |
| Cash & equivalents | $65.6M | $62.1M | $54.3M | $52.1M | $135.6M | $106.1M | — | $89.1M |
| Marketable securities (current) | $265.3M | $278.5M | $334.6M | $364.0M | $155.4M | $208.4M | — | $231.4M |
| Accounts receivable | $40.4M | $34.2M | $26.1M | $33.0M | $26.1M | $17.8M | — | $18.5M |
| Inventory | $30.5M | $28.7M | $25.8M | $22.1M | $18.9M | $19.3M | — | $18.7M |
| Other current assets | — | — | $10.0M | — | — | — | — | $8.8M |
| Property, plant & equipment | $103.0K | $1.1M | $1.1M | $237.0K | $297.0K | $462.0K | — | $632.0K |
| Intangible assets | $4.9M | $5.1M | $5.3M | $5.5M | $5.7M | $6.0M | — | $6.2M |
| Other non-current assets | — | — | $3.3M | — | — | — | — | $7.3M |
| Accounts payable | $16.2M | $12.3M | $13.9M | $13.6M | $16.0M | $11.9M | — | $12.3M |
| Accrued liabilities | — | — | $83.9M | — | — | $59.3M | — | $62.7M |
| Deferred revenue (current) | $0 | $48.0K | $194.0K | — | — | — | $1.3M | $1.3M |
| Short-term debt | $12.7M | $10.1M | $7.3M | $5.6M | $3.8M | $1.6M | — | $1.5M |
| Other current liabilities | — | — | $0 | — | $40.0M | $38.8M | — | $37.7M |
| Long-term debt | $93.4M | $98.3M | $100.9M | $103.4M | $106.0M | $107.9M | — | $108.3M |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $69.0K | $69.0K | $67.0K | $67.0K | $64.0K | $62.0K | — | $61.0K |
| Retained earnings | -$1.46B | -$1.41B | -$1.35B | -$1.30B | -$1.25B | -$1.20B | — | -$1.16B |
| Accumulated other comprehensive income (loss) | -$912.0K | $444.0K | -$796.0K | -$926.0K | -$2.2M | -$51.0K | — | -$39.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.2M | -$44.2M | -$25.4M | -$26.6M | -$23.3M | -$40.4M | -$18.8M | -$25.2M |
| Investing cash flow | $14.0M | $57.1M | $30.3M | -$246.3M | $54.0M | $24.8M | $21.2M | -$90.8M |
| Financing cash flow | -$1.2M | -$5.4M | -$2.9M | $189.3M | -$889.0K | $32.5M | $38.3M | $2.5M |
| Free cash flow | — | — | -$26.3M | — | — | — | -$18.8M | — |
| Capital expenditures | — | — | $953.0K | — | — | — | $0 | — |
| Depreciation & amortization | — | — | $500.0K | — | — | — | $700.0K | — |
| Share-based compensation | $26.1M | $23.1M | $19.3M | $18.8M | $15.9M | $12.9M | $10.6M | $11.0M |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts receivable | $6.2M | $8.1M | -$6.2M | $6.6M | $7.8M | -$687.0K | -$794.0K | $1.7M |
| Change in inventory | $2.3M | $3.1M | $4.9M | $2.5M | -$479.0K | $575.0K | $4.8M | $1.9M |
| Debt issued | — | — | $0 | — | — | — | $0 | — |
| Debt repaid | $6.9M | $4.3M | $5.4M | $5.6M | $4.3M | $4.6M | $3.8M | $3.3M |
| Tax withholding on stock comp | $1.3M | $8.5M | — | — | $0 | $0 | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $189.8M | $130.1M | $77.4M | $23.6M | $3.2M |
| Operating income | -$192.0M | -$265.5M | -$184.4M | -$179.2M | -$170.1M |
| Net income | -$196.5M | -$260.6M | -$184.7M | -$181.1M | -$69.6M |
| EPS (diluted) | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 |
| EPS (basic) | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 |
| Operating margin | -$101 | -$204 | -$238 | -$758 | -$5.4K |
| Net margin | -$104 | -$200 | -$239 | -$766 | -$2.2K |
Balance sheet
| Line item | Dec '25 | Mar '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|---|
| Total assets | $480.2M | — | $392.3M | $332.7M | $382.5M |
| Total liabilities | $210.2M | — | $227.7M | $163.0M | $118.2M |
| Stockholders' equity | $139.1M | — | $21.7M | $169.8M | $264.3M |
| Total current assets | $466.9M | — | $374.2M | $308.3M | $354.2M |
| Total current liabilities | $105.9M | — | $115.5M | $55.2M | $39.8M |
| Cash & equivalents | $54.3M | — | $89.1M | $60.1M | $127.7M |
| Marketable securities (current) | $334.6M | — | $231.4M | $215.8M | $205.6M |
| Accounts receivable | $26.1M | — | $18.5M | $14.9M | $6.2M |
| Inventory | $25.8M | — | $18.7M | $8.6M | $2.9M |
| Other current assets | $10.0M | — | $8.8M | $6.7M | $7.4M |
| Property, plant & equipment | $1.1M | — | $632.0K | $1.3M | $2.2M |
| Intangible assets | $5.3M | — | $6.2M | $7.0M | $7.9M |
| Other non-current assets | $3.3M | — | $7.3M | $15.0M | $16.7M |
| Accounts payable | $13.9M | — | $12.3M | $4.9M | $4.8M |
| Accrued liabilities | $83.9M | — | $62.7M | $48.3M | $32.9M |
| Deferred revenue (current) | $194.0K | $1.3M | $1.3M | $1.3M | $1.4M |
| Short-term debt | $7.3M | — | $1.5M | — | — |
| Other current liabilities | $0 | — | $37.7M | — | — |
| Long-term debt | $100.9M | — | $108.3M | $106.1M | — |
| Common stock & paid-in capital | $67.0K | — | $61.0K | $59.0K | $56.0K |
| Retained earnings | -$1.35B | — | -$1.16B | -$894.7M | -$710.1M |
| Accumulated other comprehensive income (loss) | -$796.0K | — | -$39.0K | $134.0K | -$92.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$115.7M | -$113.9M | -$136.2M | -$173.4M | -$146.0M |
| Investing cash flow | -$137.2M | -$48.2M | -$5.7M | $28.0M | -$62.2M |
| Financing cash flow | $218.0M | $191.2M | $74.4M | $213.8M | $166.5M |
| Free cash flow | -$116.6M | -$113.9M | -$136.2M | -$173.7M | -$146.4M |
| Capital expenditures | $953.0K | $0 | $47.0K | $281.0K | $434.0K |
| Depreciation & amortization | $500.0K | $700.0K | $900.0K | $896.0K | $816.0K |
| Share-based compensation | $66.8M | $39.7M | $32.6M | $19.8M | $20.8M |
| Deferred income taxes | $0 | $0 | $0 | — | — |
| Change in accounts receivable | $7.6M | $3.6M | $8.6M | $5.2M | $1.2M |
| Change in inventory | $7.5M | $10.1M | $5.7M | $2.8M | $11.0K |
| Debt issued | $0 | $0 | $24.4M | $72.3M | — |
| Debt repaid | $19.9M | $12.9M | $7.4M | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding RYTM as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-17 to 2026-09-14
Recent transactions
- Insiders have net sold 300,093 shares over the last 182 days, across 0 purchases and 22 sales.
- Most recent: Meeker David P (President and CEO) — Option exercise of 50,000 shares on 2026-09-14.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)300,093 sh(22 txns)
Net Shares-300,093
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Meeker David P | President and CEO | Option exercise | 2026-09-14 | 50,000 |
| Smith Hunter C | Chief Financial Officer | Option exercise | 2026-08-31 | 57,187 |
| Shulman Joseph | Chief Technical Officer | Option exercise | 2026-08-13 | 2,024 |
| Garfield Alastair | Chief Scientific Officer | Open market sale | 2026-08-13 | 2,007 |
| Lee Jennifer Kayden | EVP, Head of North America | Option exercise | 2026-08-13 | 35,000 |
| Mazabraud Yann | EVP, Head of International | Option exercise | 2026-08-12 | 46,625 |
| JEAN CHRISTOPHE | Director | Option exercise | 2026-06-23 | 4,712 |
| MCGIRR DAVID W J | Director | Option exercise | 2026-06-23 | 4,712 |
| TETRAULT LYNN A. | Director | Option exercise | 2026-06-23 | 4,712 |
| Arbuckle Stuart A | Director | Option exercise | 2026-06-23 | 4,712 |
| GOOD JENNIFER L | Director | Option exercise | 2026-06-23 | 4,712 |
| German Christopher Paul | Corporate Controller & CAO | Option exercise | 2026-05-15 | 1,687 |
| Mathers Edward T | Reporting person | Other acquisition/disposition | 2026-03-12 | 4,199 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | Meeker David P | President and CEO | Option exercise | 50,000 | $6.05 |
| 2026-09-14 | Meeker David P | President and CEO | Open market sale | 6,439 | $101.75 |
| 2026-09-14 | Meeker David P | President and CEO | Open market sale | 30,746 | $102.35 |
| 2026-09-14 | Meeker David P | President and CEO | Open market sale | 8,698 | $103.43 |
| 2026-09-14 | Meeker David P | President and CEO | Open market sale | 1,817 | $104.55 |
| 2026-09-14 | Meeker David P | President and CEO | Open market sale | 2,300 | $105.19 |
| 2026-08-31 | Smith Hunter C | Chief Financial Officer | Option exercise | 57,187 | $25.79 |
| 2026-08-31 | Smith Hunter C | Chief Financial Officer | Open market sale | 23,072 | $104.59 |
| 2026-08-31 | Smith Hunter C | Chief Financial Officer | Open market sale | 11,514 | $105.37 |
| 2026-08-31 | Smith Hunter C | Chief Financial Officer | Open market sale | 28,188 | $106.20 |
| 2026-08-13 | Shulman Joseph | Chief Technical Officer | Option exercise | 2,024 | $6.80 |
| 2026-08-13 | Shulman Joseph | Chief Technical Officer | Open market sale | 5,079 | $119.75 |
| 2026-08-13 | Garfield Alastair | Chief Scientific Officer | Open market sale | 2,007 | $116.11 |
| 2026-08-13 | Garfield Alastair | Chief Scientific Officer | Open market sale | 1,556 | $117.08 |
| 2026-08-13 | Garfield Alastair | Chief Scientific Officer | Open market sale | 3,400 | $118.28 |
| 2026-08-13 | Garfield Alastair | Chief Scientific Officer | Open market sale | 800 | $119.17 |
| 2026-08-13 | Lee Jennifer Kayden | EVP, Head of North America | Option exercise | 35,000 | $24.29 |
| 2026-08-13 | Lee Jennifer Kayden | EVP, Head of North America | Option exercise | 21,601 | $6.80 |
| 2026-08-13 | Lee Jennifer Kayden | EVP, Head of North America | Open market sale | 75,834 | $117.38 |
| 2026-08-12 | Mazabraud Yann | EVP, Head of International | Option exercise | 46,625 | $6.80 |
| 2026-08-12 | Mazabraud Yann | EVP, Head of International | Open market sale | 2,300 | $111.80 |
| 2026-08-12 | Mazabraud Yann | EVP, Head of International | Open market sale | 1,000 | $112.86 |
| 2026-08-12 | Mazabraud Yann | EVP, Head of International | Open market sale | 3,605 | $114.70 |
| 2026-08-12 | Mazabraud Yann | EVP, Head of International | Open market sale | 14,568 | $115.43 |
| 2026-08-12 | Mazabraud Yann | EVP, Head of International | Open market sale | 18,208 | $116.49 |
| 2026-08-12 | Mazabraud Yann | EVP, Head of International | Open market sale | 17,319 | $117.47 |
| 2026-07-01 | Garfield Alastair | Chief Scientific Officer | Option exercise | 4,445 | — |
| 2026-07-01 | Garfield Alastair | Chief Scientific Officer | Tax withholding | 2,150 | $110.41 |
| 2026-06-23 | JEAN CHRISTOPHE | Director | Option exercise | 4,712 | — |
| 2026-06-23 | MCGIRR DAVID W J | Director | Option exercise | 4,712 | — |
| 2026-06-23 | TETRAULT LYNN A. | Director | Option exercise | 4,712 | — |
| 2026-06-23 | Arbuckle Stuart A | Director | Option exercise | 4,712 | — |
| 2026-06-23 | GOOD JENNIFER L | Director | Option exercise | 4,712 | — |
| 2026-06-22 | TETRAULT LYNN A. | Director | Option exercise | 37,000 | $28.27 |
| 2026-06-22 | TETRAULT LYNN A. | Director | Open market sale | 37,000 | $100.32 |
| 2026-05-18 | Smith Hunter C | Chief Financial Officer | Option exercise | 3,000 | $17.87 |
| 2026-05-15 | German Christopher Paul | Corporate Controller & CAO | Option exercise | 1,687 | $56.69 |
| 2026-05-15 | German Christopher Paul | Corporate Controller & CAO | Option exercise | 1,349 | $49.23 |
| 2026-05-15 | German Christopher Paul | Corporate Controller & CAO | Option exercise | 1,406 | $17.97 |
| 2026-05-15 | German Christopher Paul | Corporate Controller & CAO | Open market sale | 4,643 | $92.21 |
| 2026-04-01 | Mazabraud Yann | EVP, Head of International | Option exercise | 12,875 | — |
| 2026-03-12 | Mathers Edward T | Reporting person | Other acquisition/disposition | 4,199 | $0.00 |
| 2026-03-04 | German Christopher Paul | Corporate Controller & CAO | Option exercise | 1,500 | $17.97 |
| 2026-03-04 | German Christopher Paul | Corporate Controller & CAO | Open market sale | 5,614 | $89.56 |
| 2026-03-02 | Mathers Edward T | Reporting person | Other acquisition/disposition | 4,198 | $0.00 |
| 2026-03-02 | Smith Hunter C | Chief Financial Officer | Option exercise | 6,099 | $6.80 |
| 2026-03-01 | German Christopher Paul | Corporate Controller & CAO | Option exercise | 1,162 | — |
| 2026-03-01 | German Christopher Paul | Corporate Controller & CAO | Tax withholding | 342 | $94.94 |
| 2026-02-19 | Smith Hunter C | Chief Financial Officer | Open market sale | 1,308 | $100.27 |
| 2026-02-19 | Smith Hunter C | Chief Financial Officer | Open market sale | 1,692 | $100.92 |
| 2026-02-19 | Smith Hunter C | Chief Financial Officer | Open market sale | 800 | $102.10 |
| 2026-02-19 | Smith Hunter C | Chief Financial Officer | Open market sale | 585 | $103.28 |
| 2026-02-17 | Smith Hunter C | Chief Financial Officer | Open market sale | 1,200 | $99.42 |
| 2026-02-17 | Smith Hunter C | Chief Financial Officer | Open market sale | 200 | $100.52 |
| 2026-02-17 | Smith Hunter C | Chief Financial Officer | Open market sale | 900 | $101.70 |
| 2026-02-17 | Smith Hunter C | Chief Financial Officer | Open market sale | 1,069 | $103.00 |
| 2026-02-17 | Smith Hunter C | Chief Financial Officer | Open market sale | 200 | $103.84 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 02:08 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-14 | 4 | 2026-09-14 | View on SEC.gov → |
| 2026-09-01 | 4 | 2026-08-31 | View on SEC.gov → |
| 2026-08-18 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-17 | 4 | 2026-08-13 | View on SEC.gov → |
| 2026-08-17 | 4 | 2026-08-13 | View on SEC.gov → |
| 2026-08-14 | 4 | 2026-08-13 | View on SEC.gov → |
| 2026-08-14 | 4 | 2026-08-12 | View on SEC.gov → |
| 2026-08-04 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-04 | 8-K | 2026-08-04 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-23 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-23 | View on SEC.gov → |
Recent news
Headlines about RYTM (Rhythm Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years
Benzinga · 2026-10-21 -
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
Yahoo Finance · 2026-10-21 -
Rhythm Pharmaceuticals Announces Third Quarter 2026 Financial Results Conference Call and Upcoming Investor Conference Participation
Quiver Quantitative · 2026-10-21 -
Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026
Yahoo Finance · 2026-10-21 -
Guggenheim keeps USD 143 target for Rhythm Pharmaceuticals stock
AD HOC NEWS · 2026-10-20 -
JPMorgan cuts target to USD 145.00 for Rhythm Pharmaceuticals stock
AD HOC NEWS · 2026-10-17 -
William Blair initiates Rhythm Pharmaceuticals stock with outperform rating By Investing.com
Investing.com Nigeria · 2026-10-16 -
JPMorgan cuts target for Rhythm Pharmaceuticals stock to USD 145.00 - ad-hoc-news.de
ad-hoc-news.de · 2026-10-15
No headlines in this category right now — try “All”.